Quarterly ResultAug 10, 2026, 09:08 AM
NEONC TECHNOLOGIES Q2 Net Loss $14.2M; Going Concern Warning
AI Summary
NEONC TECHNOLOGIES HOLDINGS, INC. reported a net loss of $(14,240,044) for the second quarter of 2026 and $(23,059,976) for the six months ended June 30, 2026. The company's cash and cash equivalents stood at $1,973,420, with an accumulated deficit of $(135,814,631), leading to a going concern warning. Despite securing $15.1 million from PIPE financing and $5 million from Series A Convertible Preferred Stock, the company lacks sufficient capital to fund operations for the next year. Clinical trials for lead products NEO100 and NEO212 are ongoing.
Key Highlights
- Net loss for Q2 2026 was $(14,240,044).
- Net loss for H1 2026 was $(23,059,976).
- Cash and cash equivalents totaled $1,973,420 as of June 30, 2026.
- Accumulated deficit reached $(135,814,631) as of June 30, 2026.
- Company issued a going concern warning due to insufficient capital.
- Secured $15.1 million from PIPE financing and $5 million from Series A Preferred Stock.
- Research and development expenses were $3,936,009 for H1 2026.
- NEO100 is in clinical trials for glioblastoma; NEO212 received FDA authorization for Phase 2a/2b.
Price Impact
More from NTHI